Publications

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review with Network Meta-Analysis of the European Myeloma Network (EMN)

Main author: Ludwig

DOI: doi.org/10.1002/ajh.70397

Publication date: June 2026

Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study.

Main author: Touzeau

Publication date: May 2026

Connected Trials: EMN34

New IMS/IMWG risk criteria by next-generation sequencing (NGS): Analysis of daratumumab benefit in both high- and standard-risk patients (pts) in the PERSEUS study.

Main author: Bertamini

Publication date: May 2026

Connected Trials: EMN17

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

Main author: Gay

DOI: 10.1038/s41591-026-04282-0 I

Publication date: April 2026

Connected Trials: EMN24

European Myeloma Network Consensus Statement on Functional High-Risk Multiple Myeloma

Main author: Lim & Spencer

DOI: 10.1002/ajh.70070

Publication date: September 2025

EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

Main author: Dimopoulos & Terpos

DOI: 10.1038/s41571-025-01041-x

Publication date: July 2025

Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network

Main author: van de Donk & Einsele

DOI: 10.1016/S2352-3026(25)00117-6

Publication date: June 2025

European Myeloma Network Group Review and Consensus Statement on Primary Plasma Cell Leukemia

Main author: Musto

DOI: 10.1016/j.annonc.2025.01.022

Publication date: February 2025

Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Main author: Bertamini

Publication date: December 2024

Connected Trials: EMN17

Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma

Main author: Broijl

Publication date: November 2024

Connected Trials: EMN15

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Main author: Sonneveld

Publication date: November 2024

Connected Trials: EMN02

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Main author: Zamagni

Publication date: November 2024

Connected Trials: EMN30

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Main author: Sonneveld

DOI: 10.1056/NEJMoa2312054

Publication date: December 2023

Connected Trials: EMN17

Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

Main author: van de Donk

Publication date: November 2023

Connected Trials: EMN26

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Main author: Gay

Publication date: November 2023

Connected Trials: EMN24

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

Main author: Dimopoulos

DOI: https://doi.org/10.1016/S2352-3026(23)00218-1

Publication date: October 2023

Connected Trials: EMN14

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study

Main author: van de Donk

DOI: https://doi.org/10.1016/S1470-2045(23)00405-9

Publication date: September 2023

Connected Trials: EMN12

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

Main author: Terpos

DOI: 10.1038/s41375-023-01920-1

Publication date: June 2023

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

Main author: Ludwig

DOI: 10.1016/S1470-2045(23)00159-6

Publication date: June 2023

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Main author: D'Agostino

DOI: 10.1200/JCO.21.02614

Publication date: May 2022

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Main author: Ludwig

DOI: https://doi.org/10.1016/S2352-3026(21)00278-7

Publication date: October 2021

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

Main author: Sonneveld

DOI: 10.1200/JCO.21.01045

Publication date: September 2021

Connected Trials: EMN02

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Main author: Dimopoulos

DOI: 10.1016/S1470-2045(21)00128-5

Publication date: June 2021

Connected Trials: EMN14

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: How to distinguish (and manage) Dr. Jekyll and Mr. Hyde

Main author: Musto

DOI: 10.3324/haematol.2021.278519

Publication date: May 2021

Carfilzomib, bendamustine, dexamethasone in patients with advanced multiple myeloma: The EMN09 Phase I/II study of the European Myeloma Network

Main author: Gramatzki

Publication date: April 2021

Connected Trials: EMN09

Filter publications

Privacy & cookies